Randomized Controlled Trial for H.pylori first line eradication therapy considering clarithromycin resistance: PCAB vs PPI

Not Applicable

• Conditions: Helicobacter pylori infection

• Registration Number: JPRN-UMIN000016337
• Lead Sponsor: Yokohama City University Hospital

Brief Summary

The ITT and PP eradication rates(ER) of V-AC in the CAM-susceptible H.pylori-infected patients were 87.3% (95%CI: 75.5-94.7%) and 88.9% (77.4-95.8%). The respective ER of PPI-AC were 76.5% (62.5-87.2%) and 86.7% (73.2-94.9%). No significant difference was observed between the groups in ITT(P = .21) or PP (P = .77) analyses. The questionnaire scores did not differ significantly between the groups. Both the ITT and PP ER of V-AC in the CAM-resistant patients were 82.9% (67.9%- 92.8%).

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-02-01
• Study Completion: 2016-10-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 147

Inclusion Criteria

Not provided

Exclusion Criteria

Past history of taking eradication therapy. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Severe liver dysfunction, Severe renal dysfunction, Severe heart dysfunction. Patients who are disqualified for the study by physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified